RGT Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

RGT Wealth Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-72,649	Closed	-$1.49M	–	96
2018 Q1	$1.49M	Hold	72,649	–	–	0.72%	22
2017 Q4	$2.06M	Hold	72,649	–	–	1.1%	17
2017 Q3	$2.26M	Hold	72,649	–	–	1.5%	14
2017 Q2	$2.3M	Buy	72,649 +13,184	+22%	+$324K	1.57%	13
2017 Q1	$1.35M	Buy	+59,465	New	+$1.47M	0.91%	15

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RGT Wealth Advisors's RETA Position: Q2 2018 in Review

RGT Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2018, closing a stake of 72,649 shares — an estimated $1.49M sold.

RGT Wealth Advisors first reported a position in RETA in Q1 2017 and held it in 5 quarters. The position peaked at $2.3M in Q2 2017. 93 funds tracked by Wall St. Rank hold RETA as of Q2 2018.

RGT Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2018 after selling out during the quarter.
RGT Wealth Advisors sold 72,649 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2018, an estimated $1.49M.
RGT Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 5 quarters.
RGT Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.3M in Q2 2017.
93 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2018.

Based on RGT Wealth Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.